Dr. Shea brings more than 25 years of leadership and industry
expertise in life sciences and biotech
PLYMOUTH MEETING, Pa.,
May 10, 2022 /PRNewswire/ -- INOVIO
(NASDAQ: INO), a biotechnology company focused on developing and
commercializing DNA medicines to help protect people from
infectious diseases and treat people with cancer and HPV-associated
diseases, today announced the appointment of Jacqueline Shea, Ph.D., as President and Chief
Executive Officer (CEO) of INOVIO, effective immediately. Dr. Shea
succeeds Dr. J. Joseph Kim in these
roles. Dr. Kim has also resigned as a member of the INOVIO
board of directors, and the board intends to appoint Dr. Shea as a
director following INOVIO's annual meeting of the stockholders on
May 16, 2022.
Mr. Simon X. Benito, Chairman of
the Board of INOVIO, said, "On behalf of the entire Board, I am
pleased to announce Dr. Shea's appointment as President and CEO of
INOVIO. Dr. Shea brings more than 25 years of experience in the
life sciences and biotech industries. Since joining as Chief
Operating Officer in March 2019, Dr.
Shea has shown exceptional leadership and technical expertise
overseeing INOVIO's manufacturing, commercial, business
development, project and alliance management operations as well as
serving as a key member of the executive team. We look forward to
Dr. Shea taking the helm during a particularly challenging period
in INOVIO's history. Her tenured leadership, deep knowledge of our
business, and broad expertise makes her an excellent choice for the
role."
Mr. Benito added, "On behalf of the Board, I would like to thank
Dr. Kim for his commitment to INOVIO and his founding vision of a
world free from disease through DNA medicines. As a co-founder of
the Company, Joseph has been a true entrepreneur and pioneer in the
field of vaccines and immunotherapies since its inception. I
am pleased that he has agreed to act in an advisory capacity to Dr.
Shea during the transition."
Dr. Shea said, "I am honored to take on the role of CEO and
grateful for the support of the Board in entrusting me to lead
INOVIO for its next chapter. While we have many challenges to face,
I believe strongly in the potential of our DNA medicines technology
and continue to be inspired by INOVIO's talented and dedicated
team. I look forward to reshaping the future of INOVIO and
advancing our efforts across multiple therapeutic areas with the
potential to improve the lives of patients globally."
Prior to joining INOVIO in March
2019, Dr. Shea served as the Chief Operating Officer and
later the Chief Executive Officer of Aeras, a not-for-profit
organization dedicated to developing new vaccines against
tuberculosis (TB). During her tenure she oversaw two major clinical
trial breakthroughs in the development of TB vaccines. Previously,
she held executive roles at Emergent BioSolutions and was also the
General Manager and Vice President of The Oxford-Emergent
Tuberculosis Consortium. A molecular biologist and cell cycle
geneticist, Dr. Shea received a BSc Hons in Applied Biology from
the University of Bath and holds a Ph.D. from the National
Institute for Medical Research in the United Kingdom. She has been named as an
inventor on more than 20 patents, has authored numerous
publications, served on multiple advisory boards and currently
serves on the board of Trustees for the Sabin Vaccine
Institute.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to potentially treat and protect
people from infectious diseases, cancer, and diseases associated
with HPV. Our DNA medicines are delivered using our proprietary
smart device to produce a robust and tolerable immune response
against targeted pathogens and cancers.
Partners and collaborators include Advaccine, ApolloBio
Corporation, AstraZeneca, The Bill & Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations, Defense Advanced
Research Projects Agency/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense/Department
of Defense, HIV Vaccines Trial Network, International Vaccine
Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium,
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Ology Bioservices,
the Parker Institute for Cancer Immunotherapy, Plumbline Life
Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher
Scientific, University of Pennsylvania,
Walter Reed Army Institute of Research, and The Wistar Institute.
For more information, visit www.inovio.com.
CONTACTS:
Investors: Ben Matone,
484-362-0076, ben.matone@inovio.com
Media: Jeff Richardson, 267-440-4211,
jrichardson@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-announces-the-appointment-of-jacqueline-shea-phd-as-chief-executive-officer-301544321.html
SOURCE INOVIO Pharmaceuticals, Inc.